UroGen Pharma Ltd. - Ordinary Shares (URGN): Price and Financial Metrics
URGN Price/Volume Stats
Current price | $15.00 | 52-week high | $24.13 |
Prev. close | $14.96 | 52-week low | $8.00 |
Day low | $14.56 | Volume | 175,700 |
Day high | $15.25 | Avg. volume | 345,808 |
50-day MA | $16.75 | Dividend yield | N/A |
200-day MA | $14.88 | Market Cap | 351.81M |
URGN Stock Price Chart Interactive Chart >
URGN POWR Grades
- URGN scores best on the Growth dimension, with a Growth rank ahead of 82.24% of US stocks.
- URGN's strongest trending metric is Growth; it's been moving up over the last 26 weeks.
- URGN's current lowest rank is in the Momentum metric (where it is better than 10.87% of US stocks).
URGN Stock Summary
- UROGEN PHARMA LTD's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 4.69% of US listed stocks.
- URGN's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 5.73% of US stocks.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for URGN comes in at -32.87% -- higher than that of just 10.72% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to UROGEN PHARMA LTD are INTZ, AXTI, SERA, LAW, and TTOO.
- URGN's SEC filings can be seen here. And to visit UROGEN PHARMA LTD's official web site, go to www.urogen.com.
URGN Valuation Summary
- URGN's price/sales ratio is 6; this is 172.73% higher than that of the median Healthcare stock.
- URGN's price/sales ratio has moved down 4.4 over the prior 81 months.
Below are key valuation metrics over time for URGN.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
URGN | 2023-12-29 | 6.0 | -11.0 | -4.4 | -4.9 |
URGN | 2023-12-28 | 6.0 | -11.1 | -4.4 | -4.9 |
URGN | 2023-12-27 | 5.8 | -10.6 | -4.2 | -4.7 |
URGN | 2023-12-26 | 5.8 | -10.6 | -4.2 | -4.7 |
URGN | 2023-12-22 | 5.8 | -10.7 | -4.3 | -4.7 |
URGN | 2023-12-21 | 6.0 | -11.1 | -4.4 | -4.9 |
URGN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- URGN has a Quality Grade of D, ranking ahead of 11.82% of graded US stocks.
- URGN's asset turnover comes in at 0.249 -- ranking 178th of 682 Pharmaceutical Products stocks.
- BIIB, TECH, and ZGNX are the stocks whose asset turnover ratios are most correlated with URGN.
The table below shows URGN's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 0.249 | 0.897 | -1.677 |
2021-03-31 | 0.148 | 0.901 | -1.535 |
2020-12-31 | 0.080 | 0.914 | -1.308 |
2020-09-30 | 0.023 | 0.907 | -1.202 |
2020-06-30 | 0.002 | 0.871 | -1.036 |
2020-03-31 | 0.000 | 1.000 | -0.926 |
URGN Price Target
For more insight on analysts targets of URGN, see our URGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $42.60 | Average Broker Recommendation | 1.33 (Strong Buy) |
UroGen Pharma Ltd. - Ordinary Shares (URGN) Company Bio
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing therapies for urological pathologies. The company is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer. The company was founded in 2004 and is based in Raanana, Israel.
Latest URGN News From Around the Web
Below are the latest news stories about UROGEN PHARMA LTD that investors may wish to consider to help them evaluate URGN as an investment opportunity.
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PRINCETON, N.J., December 08, 2023--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units ("RSUs") to 17 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercial launch of Jelmyto® (mitomycin) for pyelocalyceal solution, UroGen’s first approved product, and the |
Shareholders in UroGen Pharma (NASDAQ:URGN) are in the red if they invested five years agoUroGen Pharma Ltd. ( NASDAQ:URGN ) shareholders should be happy to see the share price up 17% in the last month. But... |
UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2023 Earnings Call TranscriptUroGen Pharma Ltd. (NASDAQ:URGN) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Good morning, ladies and gentlemen, and thank you for standing by, and welcome to the UroGen Pharma Q3 2023 Earnings Call. Please be advised that today’s conference is being recorded. I would now like to hand the conference over to your speaker […] |
UroGen Pharma Ltd (URGN) Reports Growth in Q3 Revenue and Progress in Clinical TrialsNet Revenue Rises as Company Advances with UGN-102 Clinical Development |
UroGen Pharma Reports Third Quarter 2023 Financial ResultsPRINCETON, N.J., November 14, 2023--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the third quarter ended September 30, 2023, and provided an overview of recent developments. |
URGN Price Returns
1-mo | -17.45% |
3-mo | 0.00% |
6-mo | 7.07% |
1-year | 79.00% |
3-year | -19.01% |
5-year | -59.39% |
YTD | 0.00% |
2023 | 69.11% |
2022 | -6.73% |
2021 | -47.23% |
2020 | -46.00% |
2019 | -22.50% |
Loading social stream, please wait...